Biofluity's remote heart monitoring device, Bioflux, has been approved by the US Food and Drug Administration (FDA). The Bioflux device includes an electrocardiogram (ECG) monitor and an ECG monitoring software that allows doctors to remotely monitor patients. Patients with cardiovascular coronary disease have a diagnosis based on arrhythmia or other cardiac information.
This remote monitoring system contributes to the early detection of cardiovascular disease and is expected to contribute to the post-treatment orientation of the public health system to preventive medical guidance. Biotricity has started production of Bioflux and is ready for volume production. Waqiaas Al-Siddiq, founder and CEO of Biotricity, said that the required manufacturing equipment is ready and ready for mass production.
Al-Siddiq also pointed out that in addition to Bioflux, the company continues to develop remote biometrics for other chronic diseases, hoping to assist medical institutions in diagnosing, treating, and monitoring patients' conditions. This patient remote monitoring platform can also be applied to other industries, and other medical-oriented applications have also been developed.
KENNEDE ELECTRONICS MFG CO.,LTD. , https://www.axavape.com